The mechanisms that determine differences in growth inhibition in dasatinib-sensitive or -resistant cell lines and in BCP-ALL with different karyotypes in response to TGF-β1 were not systematically investigated in the study. Here, TGFB1 is linked to acute lymphoblastic leukemia.